242 related articles for article (PubMed ID: 35837161)
41. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
42. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J
Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078
[TBL] [Abstract][Full Text] [Related]
43. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
44. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
45. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
[TBL] [Abstract][Full Text] [Related]
46. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
[TBL] [Abstract][Full Text] [Related]
47. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
48. A systematic review and network meta-analysis of post-imatinib therapy in advanced gastrointestinal stromal tumour.
Shah K; Chan KKW; Ko YJ
Curr Oncol; 2017 Dec; 24(6):e531-e539. PubMed ID: 29270063
[TBL] [Abstract][Full Text] [Related]
49. Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor.
Singeltary B; Ghose A; Sussman J; Choe K; Olowokure O
J Gastrointest Oncol; 2014 Feb; 5(1):E27-9. PubMed ID: 24490049
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
51. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
53. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
54. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy.
Ferraro D; Zalcberg J
Ther Adv Med Oncol; 2014 Sep; 6(5):222-8. PubMed ID: 25342989
[TBL] [Abstract][Full Text] [Related]
55. New paradigms in gastrointestinal stromal tumour management.
Blay JY
Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
[TBL] [Abstract][Full Text] [Related]
56. Precision medicine in gastrointestinal stromal tumors.
Florou V; Trent JC; Wilky BA
Discov Med; 2019; 28(155):267-276. PubMed ID: 32053767
[TBL] [Abstract][Full Text] [Related]
57. 2023 GEIS Guidelines for gastrointestinal stromal tumors.
Serrano C; Martín-Broto J; Asencio-Pascual JM; López-Guerrero JA; Rubió-Casadevall J; Bagué S; García-Del-Muro X; Fernández-Hernández JÁ; Herrero L; López-Pousa A; Poveda A; Martínez-Marín V
Ther Adv Med Oncol; 2023; 15():17588359231192388. PubMed ID: 37655207
[TBL] [Abstract][Full Text] [Related]
58. Current research and treatment for gastrointestinal stromal tumors.
Lim KT; Tan KY
World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
[TBL] [Abstract][Full Text] [Related]
59. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
60. Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs).
Vetto JT
Onco Targets Ther; 2009 Feb; 2():151-9. PubMed ID: 20616902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
